Strategies used by human immunodeficiency virus that allow persistent viral replication

Nature Medicine

Volumn 5, Issue 7, 1999, Pages 723-725

  Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; NOTE; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANIMALS; ANTIGENIC VARIATION; CD4-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, ENV; HIV; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS INTEGRATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033021576     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/10439     Document Type: Note

References (43)

1. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
2. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
3. Wyand, M.S. et al. Cellular localization of simian immunodeficiency virus in lymphoid tissues. II. In situ hybridization. American Journal of Pathology 134, 385-393 (1989).
4. Ringler, D.J. et al. Cellular localization of simian immunodeficiency virus in lymphoid tissues. I. Immunohistochemistry and electron microscopy. Am. J. Pathol. 134, 373-383 (1989).
5. Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358 (1993).
6. Binley, J.M. et al. Differential Regulation of the antibody responses to gag and env proteins of human immunodeficiency virus Type 1. Virology 71, 2799-2809 (1997).
7. Schmitz, J.E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857-860 (1999).
8. Ogg, G.S. et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106 (1998).
9. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
10. Mansky, L.M. & Temin, H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69, 5087-5094 (1995).
11. Coffin, J.M. Genetic variation in AIDS viruses. Cell 46, 1-4 (1986).
12. Burns, D.P.W. & Desrosiers, R.C. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J. Virol. 65, 1843-1854 (1991).
13. Myers, G. et al. in Human Retroviruses and AIDS 1995 (Los Alamos National Laboratory, Los Alamos, New Mexico, 1995).
14. Burns, D.P.W., Collignon, C. & Desrosiers, R.C. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J. Virol. 67, 4104-4113 (1993).
15. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
16. Goulder, P.J.R. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3, 212-217 (1997).
17. Lane, H.C. et al. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N. Engl. J. Med. 313, 79 (1985).
18. Clerici, M. et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymtomatic HIV-seropositive individuals. Nature 339, 383 (1989).
19. Rosenberg, E.S. & Walker, B.D. HIV type 1-specific helper T cells: A critical host defense. AIDS Res. Hum. Retroviruses 14, S-143-S-147 (1998).
20. + T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
21. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med. 5, 518-525 (1999).
22. Greenough, T.C., Sullivan, J.L. & Desrosiers, R.C. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N. Engl. J. Med. 340, 236-237 (1999).
23. Dyer, W.B. et al. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney blood bank cohort patients infected with nef-defective HIV type 1. J. Virol. 73, 436-443 (1999).
24. Gauduin, M.-C., Glickman, R.L., Ahmad, S., Yilma, T. & Johnson, R.P. Characterization of SIV-specific CD4+T helper proliferative responses in macaques immunized with live attenuated SIV. J. Med. Primatol. (in the press).
25. Fouts, T.R., Binley, J.M., Trkola, A., Robinson, J.E. & Moore, J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71, 2779-2785 (1997).
26. Parren, P.W.H.I. et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 72, 3512-3519 (1998).
27. Sattentau, Q.J. & Moore, J.P. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J. Exp. Med. 182, 185-196 (1995).
28. Burton, D.R. A vaccine for HIV type 1: The antibody perspective. Proc. Natl. Acad. Sci. USA 94, 10018-10023 (1997).
29. Moore, J.P. et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109 (1995).
30. Takefman, D.M., Sullivan, B.L., Sha, B.E. & Spear, G.T. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 246, 370-378 (1998).
31. Chan, D.C., Fass, D., Berger, J.M. & Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
32. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W. & Sodroski, J. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
33. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J. & Wiley, D.C. Atomic structure of the ectodomain form HIV-1 gp41. Nature 387, 426-430 (1997).
34. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711 (1998).
35. Reitter, J.N., Means, R.E. & Desrosiers, R.C. A role for carbohydrates in immune evasion in AIDS. Nature Med. 4, 679-684 (1998).
36. LaCasse, R.A. et al. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 283, 357-362 (1999).
37. Ploegh, H.L. Viral strategies of immune evasion. Science 280, 248-253 (1998).
38. Andersson, M., Paabo, S., Nilsson, T. & Peterson, P.A. Impaired intracellular transport of class 1 MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 43, 215-222 (1985).
39. Burgert, H.-G. & Kvist, S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class 1 antigens. Cell 41, 987-997 (1985).
40. York, I.A. et al. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77, 525-535 (1994).
41. Greenberg, M.E. et al. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J 16, 6964-6976 (1997).
42. Schwartz, O., Marechal, V., LeGall, S., Lemonnier, F. & Heard, J.-M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 nef protein. Nature Med. 2, 338-342 (1996).
43. Collins, K.L., Chen, B.K., Kalams, S.A., Walker, B.D. & Baltimore, D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397-401 (1998).